Reduction in snoring with phosphocholinamin, a long-acting tissue-lubricating agent

Area of Science:

• Otorhinolaryngology
• Biomaterials Science

Background:

• Snoring is a common condition affecting sleep quality and potentially indicating underlying health issues.
• Current treatments for snoring have varying efficacy and patient compliance.
• Phosphocholinamin is a novel long-acting lubricating and coating agent with potential therapeutic applications.

Purpose of the Study:

• To evaluate the efficacy of phosphocholinamin nasal drops in reducing snoring.
• To compare the effects of phosphocholinamin with a placebo in snoring reduction.

Main Methods:

• A randomized, placebo-controlled study involving 12 participants with snoring.
• Administration of phosphocholinamin nasal drops to six participants and placebo (tap water) to six participants.
• Continuous noise level measurement using a microphone near the cricothyroid notch to assess snoring intensity and frequency (snoring index).

Main Results:

• The phosphocholinamin group showed a statistically significant reduction in maximum nocturnal decibel level (13 +/- 3%) and snoring index (25 +/- 12%).
• The placebo group exhibited an increase in maximum nocturnal decibel level (9 +/- 22%) and snoring index (1 +/- 20%).
• The observed differences between the treatment and placebo groups were statistically significant (P < .05).

Conclusions:

• Phosphocholinamin demonstrates significant efficacy in reducing snoring intensity and frequency.
• This agent presents a promising new medical alternative for snoring treatment.
• Further clinical trials are recommended to confirm these findings and explore long-term effects.